Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Author:

Montironi CarlaORCID,Castet FlorianORCID,Haber Philipp K,Pinyol RoserORCID,Torres-Martin Miguel,Torrens LauraORCID,Mesropian Agavni,Wang Huan,Puigvehi Marc,Maeda Miho,Leow Wei Qiang,Harrod Elizabeth,Taik Patricia,Chinburen Jigjidsuren,Taivanbaatar Erdenebileg,Chinbold Enkhbold,Solé Arqués Manel,Donovan Michael,Thung Swan,Neely Jaclyn,Mazzaferro Vincenzo,Anderson Jeffrey,Roayaie Sasan,Schwartz Myron,Villanueva Augusto,Friedman Scott LORCID,Uzilov Andrew,Sia DanielaORCID,Llovet Josep MORCID

Abstract

ObjectiveWe previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.DesignWe performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients.ResultsOur integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched inTP53mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched inCTNNB1mutations (93% vs 27%, p<0.001) andPTK2overexpression due to gene amplification and promoter hypomethylation.CTNNB1mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes.ConclusionWe have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinctCTNNB1patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.

Funder

Dr. Franklin M. Klion Young Scientist Research Award

Generalitat de Catalunya

National Cancer Institute

PhD Scientist Innovative Research Award

Instituto de Salud Carlos III

Samuel Waxman Cancer Research Foundation

Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears

Cancer Research UK

Associazione Italiana per la Ricerca sul Cancro

U.S. Department of Defense

Tisch Cancer Institute

Horizon 2020 Framework Programme

Deutsche Forschungsgemeinschaft

Fundación Científica Asociación Española Contra el Cáncer

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Agència de Gestió d’Ajuts Universitaris i de Recerca

Bristol-Myers Squibb

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

BMJ

Subject

Gastroenterology

Reference47 articles.

1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021

2. Hepatocellular carcinoma;Villanueva;N Engl J Med Overseas Ed,2019

3. Immunotherapies for hepatocellular carcinoma;Llovet;Nat Rev Clin Oncol,2021

4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med Overseas Ed,2020

5. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;J Hepatol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3